| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective … W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ... The lancet oncology 11 (8), 753-762, 2010 | 2752 | 2010 |
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1324 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1271 | 2014 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 965 | 2023 |
| Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr) E Cacciari, S Milani, A Balsamo, E Spada, G Bona, L Cavallo, F Cerutti, ... Journal of endocrinological investigation 29 (7), 581-593, 2006 | 930 | 2006 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 760 | 2017 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 755 | 2009 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 680 | 2021 |
| Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial … R Gralla, M Lichinitser, S Van Der Vegt, H Sleeboom, J Mezger, ... Annals of Oncology 14 (10), 1570-1577, 2003 | 658 | 2003 |
| Gut microbiota and cancer: from pathogenesis to therapy S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ... Cancers 11 (1), 38, 2019 | 640 | 2019 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non—small-cell lung cancer receiving … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... Journal of Clinical Oncology 23 (28), 6865-6872, 2005 | 599 | 2005 |
| Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study M Muscaritoli, S Lucia, A Farcomeni, V Lorusso, V Saracino, C Barone, ... Oncotarget 8 (45), 79884, 2017 | 552 | 2017 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... Journal of clinical oncology 27 (16), 2622-2629, 2009 | 514 | 2009 |
| Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ... Clinical Cancer Research 9 (8), 2893-2897, 2003 | 483 | 2003 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The lancet oncology 24 (12), 1399-1410, 2023 | 409 | 2023 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 398 | 2007 |
| Italian cross-sectional growth charts for height, weight and BMI (6–20 y) E Cacciari, S Milani, A Balsamo, F Dammacco, F De Luca, F Chiarelli, ... European journal of clinical nutrition 56 (2), 171-180, 2002 | 398 | 2002 |
| Pamidronate induces modifications of circulating angiogenetic factors in cancer patients D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ... Clinical Cancer Research 8 (5), 1080-1084, 2002 | 364 | 2002 |
| Assessment of a HER2 scoring system for colorectal cancer: results from a validation study E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ... Modern Pathology 28 (11), 1481-1491, 2015 | 361 | 2015 |
| The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first … G Fucà, V Guarini, C Antoniotti, F Morano, R Moretto, S Corallo, ... British journal of cancer 123 (3), 403-409, 2020 | 359 | 2020 |
